|Other Names||Coagulation factor XII, Hageman factor, HAF, Coagulation factor XIIa heavy chain, Beta-factor XIIa part 1, Beta-factor XIIa part 2, Coagulation factor XIIa light chain, F12|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then trypsin cleaves it to beta- factor XIIa. Alpha-factor XIIa activates factor XI to factor XIa.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes coagulation factor XII which circulatesin blood as a zymogen. This single chain zymogen is converted to atwo-chain serine protease with an heavy chain (alpha-factor XIIa)and a light chain. The heavy chain contains two fibronectin-typedomains, two epidermal growth factor (EGF)-like domains, a kringledomain and a proline-rich domain, whereas the light chain containsonly a catalytic domain. On activation, further cleavages takesplace in the heavy chain, resulting in the production ofbeta-factor XIIa light chain and the alpha-factor XIIa light chainbecomes beta-factor XIIa heavy chain. Prekallikrein is cleaved byfactor XII to form kallikrein, which then cleaves factor XII firstto alpha-factor XIIa and then to beta-factor XIIa. The activefactor XIIa participates in the initiation of blood coagulation,fibrinolysis, and the generation of bradykinin and angiotensin. Itactivates coagulation factors VII and XI. Defects in this gene donot cause any clinical symptoms and the sole effect is thatwhole-blood clotting time is prolonged.
Anton, A.I., et al. Ann. Hematol. 89(11):1147-1154(2010)Corral, J., et al. Blood Coagul. Fibrinolysis 21(7):632-639(2010)Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Romero, R., et al. Am. J. Obstet. Gynecol. 202 (5), 431 (2010) :
If you have any additional inquiries please email technical services at firstname.lastname@example.org.